Compare Sun Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs LUPIN - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA LUPIN SUN PHARMA/
LUPIN
 
P/E (TTM) x 27.4 -132.7 - View Chart
P/BV x 2.8 3.0 93.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   LUPIN
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
LUPIN
Mar-19
SUN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs679986 68.8%   
Low Rs375720 52.1%   
Sales per share (Unadj.) Rs121.1369.5 32.8%  
Earnings per share (Unadj.) Rs13.413.4 99.8%  
Cash flow per share (Unadj.) Rs20.737.4 55.3%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.6303.7 56.8%  
Shares outstanding (eoy) m2,399.26452.49 530.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.3 188.4%   
Avg P/E ratio x39.463.6 61.9%  
P/CF ratio (eoy) x25.522.8 111.7%  
Price / Book Value ratio x3.12.8 108.7%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,650386,064 327.6%   
No. of employees `00017.517.7 99.0%   
Total wages/salary Rs m59,67131,513 189.4%   
Avg. sales/employee Rs Th16,608.19,453.8 175.7%   
Avg. wages/employee Rs Th3,409.61,782.0 191.3%   
Avg. net profit/employee Rs Th1,833.8343.0 534.6%   
INCOME DATA
Net Sales Rs m290,659167,182 173.9%  
Other income Rs m10,2553,640 281.7%   
Total revenues Rs m300,914170,822 176.2%   
Gross profit Rs m63,07628,822 218.8%  
Depreciation Rs m17,53310,850 161.6%   
Interest Rs m5,5533,078 180.4%   
Profit before tax Rs m50,24618,534 271.1%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-12,144-3,400 357.2%   
Tax Rs m6,0099,017 66.6%   
Profit after tax Rs m32,0936,066 529.1%  
Gross profit margin %21.717.2 125.9%  
Effective tax rate %12.048.7 24.6%   
Net profit margin %11.03.6 304.3%  
BALANCE SHEET DATA
Current assets Rs m310,692138,536 224.3%   
Current liabilities Rs m173,39661,299 282.9%   
Net working cap to sales %47.246.2 102.2%  
Current ratio x1.82.3 79.3%  
Inventory Days Days9984 118.2%  
Debtors Days Days112112 99.2%  
Net fixed assets Rs m232,477127,516 182.3%   
Share capital Rs m2,399905 265.1%   
"Free" reserves Rs m411,691136,517 301.6%   
Net worth Rs m414,091137,422 301.3%   
Long term debt Rs m15,22666,417 22.9%   
Total assets Rs m646,938279,494 231.5%  
Interest coverage x10.07.0 143.1%   
Debt to equity ratio x00.5 7.6%  
Sales to assets ratio x0.40.6 75.1%   
Return on assets %5.83.3 177.9%  
Return on equity %7.84.4 175.6%  
Return on capital %10.28.9 114.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02559,414 111.1%   
Fx outflow Rs m38,61022,282 173.3%   
Net fx Rs m27,41537,132 73.8%   
CASH FLOW
From Operations Rs m21,96516,660 131.8%  
From Investments Rs m-6,813-32,825 20.8%  
From Financial Activity Rs m-27,3057,441 -366.9%  
Net Cashflow Rs m-8,442-8,724 96.8%  

Share Holding

Indian Promoters % 63.7 46.6 136.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 31.9 72.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.1 82.2%  
Shareholders   133,026 98,259 135.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare SUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

This Ratio Says Smallcaps Are Your Best Bet to Ride the Post Covid Market Rebound(Profit Hunter)

Jun 23, 2020

Here's why I believe that post Covid rebound in smallcaps will be much sharper than largecaps.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS